<DOC>
	<DOCNO>NCT02252393</DOCNO>
	<brief_summary>This randomize clinical trial study intracorporeal extracorporeal urinary diversion robotic assist radical cystectomy reduce complication patient bladder cancer . Radical cystectomy surgery remove entire bladder well nearby tissue organ . After bladder remove , urinary diversion ( surgical procedure make new way urine leave body ) perform . It yet know whether intracorporeal ( within body ) extracorporeal ( outside body ) urinary diversion well method patient bladder cancer undergo robotic assisted radical cystectomy .</brief_summary>
	<brief_title>Urinary Diversion During Robotic Assisted Radical Cystectomy Patients With Bladder Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To compare perioperative outcome complication robotic assist radical cystectomy ( RARC ) intracorporeal urinary diversion ( IUD ) RARC extracorporeal urinary diversion ( EUD ) prospective randomize fashion . SECONDARY OBJECTIVES : I . Time passage flatus . II . Analgesic requirement ( narcotic use ) . III . Hospital length stay . IV . Total operate time . V. Estimated blood loss . VI . Readmission rate . VII . Bladder Cancer Index Questionnaire . VIII . Ureteral stricture . IX . Stomal stenosis . X . Disease recurrence . XI . Secondary procedure . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients undergo RARC IUD . ARM II : Patients undergo RARC EUD . After completion study treatment , patient follow within 90 day 2-5 year .</detailed_description>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>Grade G1 G3 bladder cancer T stage : cTis T2 N0 M0 American Society Anesthesiologists ( ASA ) &lt; 4 Informed consent Eastern Cooperative Oncology Group ( ECOG ) performance status 2 good Hemoglobin ( Hgb ) &gt; 8.0 g/dL White blood cell ( WBC ) &gt; 2.0 k/uL Platelets &gt; 50,000 Creatinine &lt; 3.0 x upper limit normal ( ULN ) Aspartate aminotransferase ( AST ) &lt; 5.0 x ULN Alanine transaminase ( ALT ) &lt; 5.0 x ULN Patient unsuitable refuse radical cystectomy T stage ≥ T3 ( mass extend outside bladder ) Gross nodal metastatic disease presentation ( ≥ N1 , M1 ) Prior pelvic radiation Prior open laparoscopic/robotic bladder prostate surgery Prior colorectal surgery history inflammatory bowel disease Body mass index ( BMI ) ≥ 40 ECOG performance status 3 bad History coagulopathy bleeding disorder Chronic steroid use Patients end stage renal disease ( ESRD ) and/or dialysis</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>